Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Neoplasm Metastasis 2Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Urothelial Carcinoma 1Melanoma 1Lymphatic Metastasis 1Head and Neck Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 10 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

enzalutamide 21Magnetic Resonance Spectroscopy 21apalutamide 17Androgen Antagonists 14Specimen Handling 13Prednisone 13Abiraterone Acetate 13abiraterone 9Docetaxel 9Radiotherapy 8Biopsy 8darolutamide 7Radiosurgery 7Pluvicto 7Nivolumab 7cabazitaxel 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6Lutetium 5radium Ra 223 dichloride 4pembrolizumab 4niraparib 4gallium 68 PSMA-11 4cabozantinib 4bicalutamide 4atezolizumab 4Watchful Waiting 4Surveys and Questionnaires 4Standard of Care 4Radiotherapy, Intensity-Modulated 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × avelumab × 30 days × Clear all
NCT04071236 2026-06-05

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡